Cardiometabolic & kidneySecondary analysis
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis
- Prespecified subgroup analysis of the FIND-CKD randomised trial
- placebo-controlled
- 1:1 randomisation
Authors' conclusion
Finerenone slowed eGFR decline and reduced kidney-cardiovascular outcome risk in participants with hypertensive nephropathy
Study context
- Population
- Adults with non-diabetic CKD (estimated glomerular filtration rate (eGFR) 25-<90 mL/min/1.73 m², urinary albumin-to-creatinine ratio (UACR) 200–3500 mg/g) and investigator-reported hypertensive nephropathyof 1584 randomised
- Participants
- 459 adults
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Total eGFR slope
- Follow-up
- Baseline to Month 32
Primary result
As reported in the abstract
Total eGFR slope, hypertensive nephropathy subgroup
Difference
0.65 mL/min/1.73 m²/year
95% CI 0.02–1.29
P = 0.044
Finerenone vs Placebo
difference 0.65 mL/min/1.73 m²/year (95% CI 0.02–1.29); P = 0.044
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Kidney-CV composite (sustained ≥57% eGFR decline, kidney failure, HF hospitalisation or CV death), hypertensive nephropathy subgroup | 0.61 (0.38–0.99) | P = 0.045 | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | difference (mmHg) | P value |
|---|---|---|
| SBP and UACR · Month 6 · SBP | −3.5 |
- Systolic blood pressure (SBP) and UACR — UACR reduction with finerenone vs placebo
- 33%
- Kidney-CV composite (sustained ≥57% eGFR decline, kidney failure, HF hospitalisation or CV death), hypertensive nephropathy subgroup: consistent irrespective of baseline SBP (interaction P 0.91)
Safety
Hyperkalaemia
Hyperkalaemia-related discontinuation
Original publication
Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis. Eur Heart J. Published 30 August 2026. doi:10.1093/eurheartj/ehag729
Summarised from the published abstract; every number is checked against it